Recipient/donor origin of antigen-specific TCCs derived from antigen-specific TCLs or from pools of positive wells recovered from LDAs
. | 3-5 mo after CBT . | . | 12-15 mo after BMT . | . | ||
---|---|---|---|---|---|---|
Patient no. . | HCMV . | CA . | HCMV . | CA . | ||
CBT-sib | ||||||
1* | 0/6 | 0/2 | 0/1 | 0/2 | ||
2* | 1/10 | 0/1 | 2/3 | 0/1 | ||
3* | ND | 1/62 | ND | 2/13 | ||
4* | ND | 7/4 | ND | 4/1 | ||
5* | ND | 0/51 | ND | 0/47 | ||
6† | 6/8 | ND | 4/8 | ND | ||
9† | 15/0 | ND | 14/0 | ND | ||
CBT-ud | ||||||
12* | ND | ND | 0/12 | ND | ||
13* | ND | 0/32 | ND | 0/16 |
. | 3-5 mo after CBT . | . | 12-15 mo after BMT . | . | ||
---|---|---|---|---|---|---|
Patient no. . | HCMV . | CA . | HCMV . | CA . | ||
CBT-sib | ||||||
1* | 0/6 | 0/2 | 0/1 | 0/2 | ||
2* | 1/10 | 0/1 | 2/3 | 0/1 | ||
3* | ND | 1/62 | ND | 2/13 | ||
4* | ND | 7/4 | ND | 4/1 | ||
5* | ND | 0/51 | ND | 0/47 | ||
6† | 6/8 | ND | 4/8 | ND | ||
9† | 15/0 | ND | 14/0 | ND | ||
CBT-ud | ||||||
12* | ND | ND | 0/12 | ND | ||
13* | ND | 0/32 | ND | 0/16 |